Hepatitis C virus (HCV) infects 185 million persons worldwide, is the leading indication for liver transplantation and, in the US, has a higher mortaliy rate than HIV. The annual healthcare costs associated with HCV exceed $9 billion, a number expected to increase as the epidemic matures and end stage liver disease peaks over the next decade. By virtue of its remarkable predilection for persistence, HCV is a model chronic viral infection. Mounting evidence supports the idea that HCV, while inducing type I IFN expression, maintains chronicity by virtue of global suppression of host innate and adaptive immunity. The mainstay of treatment for the last two decades, IFN-?-based regimens are ineffective in many patient subgroups and have significant side effects. The recent development of highly effective direct acting antivirals (DAA) against HCV promises to alter the landscape of this devastating infection by offering curative therapy without IFN. However, it remains essential that we understand what type of immunity remains following pharmacological eradication of the virus because: a) many HCV infected subjects remain at risk for re-infection;and b) DAAs are only partially effective in some patient subgroups, particularly those with past treatment with IFN. The imminent availability of IFN-free treatment for HCV offers an unprecedented opportunity to understand broad questions about alterations in immunity in humans with cure of chronic infections. Until now, mechanistic dissection of human immune responses has been challenging due to limited ability to directly perturb the system. The organizing principle of this U19 Program therefore, is to capitalize on the unique opportunity to, for the first time, cure chronic viral infection in humans without immune modulation and interrogate the immunological changes that ensue. Thus, we have formulated the following central hypothesis for this Program: DAA-mediated cure of chronic HCV infection will lead to partial """"""""resetting"""""""" of some immune abnormalities, but specific immunological defects will persist in some subjects that prevent development of optimal immunity to HCV. We will test this hypothesis through a set of integrated Projects and Cores.

Public Health Relevance

There are 185 million people worldwide chronically infected with HCV and this infection is a major cause of liver failure and liver cancer with annual health care costs of ~$9 billion in the US. New antiviral drugs will have a major impact, but many patients are at risk for re-infection. Thus, it is imperative that we understand what type of immunity persists following cure of HCV infection to not only determine whether drug cured subjects have immunity but also to further understand immunity to chronic infections in general.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-LAR-I (J1))
Program Officer
Quill, Helen R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts General Hospital
United States
Zip Code
Rowe, Ian A; Tully, Damien C; Armstrong, Matthew J et al. (2016) Effect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation. Liver Transpl 22:287-97
Fergusson, J R; Hühn, M H; Swadling, L et al. (2016) CD161(int)CD8+ T cells: a novel population of highly functional, memory CD8+ T cells enriched within the gut. Mucosal Immunol 9:401-13
Attanasio, John; Wherry, E John (2016) Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity 44:1052-68
Llibre, Alba; López-Macías, Constantino; Marafioti, Teresa et al. (2016) LLT1 and CD161 Expression in Human Germinal Centers Promotes B Cell Activation and CXCR4 Downregulation. J Immunol 196:2085-94
Kurioka, Ayako; Walker, Lucy J; Klenerman, Paul et al. (2016) MAIT cells: new guardians of the liver. Clin Transl Immunology 5:e98
van Wilgenburg, Bonnie; Scherwitzl, Iris; Hutchinson, Edward C et al. (2016) MAIT cells are activated during human viral infections. Nat Commun 7:11653
Jeffery, Hannah C; van Wilgenburg, Bonnie; Kurioka, Ayako et al. (2016) Biliary epithelium and liver B cells exposed to bacteria activate intrahepatic MAIT cells through MR1. J Hepatol 64:1118-27
Kelly, Christabel; Swadling, Leo; Capone, Stefania et al. (2016) Chronic hepatitis C viral infection subverts vaccine-induced T-cell immunity in humans. Hepatology 63:1455-70
Chusri, Pattranuch; Kumthip, Kattareeya; Hong, Jian et al. (2016) HCV induces transforming growth factor β1 through activation of endoplasmic reticulum stress and the unfolded protein response. Sci Rep 6:22487
Swadling, Leo; Halliday, John; Kelly, Christabel et al. (2016) Highly-Immunogenic Virally-Vectored T-cell Vaccines Cannot Overcome Subversion of the T-cell Response by HCV during Chronic Infection. Vaccines (Basel) 4:

Showing the most recent 10 out of 128 publications